Pharmaceutics, Volume 14, Issue 1
2022 January - 218 articles
Cover Story: The airways of an asthmatic are battlefields of unchecked inflammation and environmental triggers. In addition to traditional therapies, new biologic therapies targeting IL-5 and other key interleukins are used to control asthma and prevent fibrotic airway damage. However, as current therapies rely on mechanical delivery through inhalation devices, delivery into the deep lungs past mucosal barriers remains a challenge to conquering exacerbations. Recently, a new frontier of asthma therapy based on custom nanoscale particles engineered to deliver medicines under such conditions has been explored. This article reviews current technology and future directions of such liposomal, nanoparticulate, and exosomal drug delivery for asthma in addition to brief reviews on current medicines and mechanical delivery systems for asthma treatment. View this paper. - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.